Meeting Overview: Interferon Lambda - Disease Impact and Therapeutic Potential

Authors

Thomas R. O'Brien, National Cancer Institute (NCI)
Howard A. Young, National Cancer Institute at FrederickFollow
Raymond P. Donnelly, Food and Drug Administration
Ludmila Prokunina-Olsson, National Cancer Institute (NCI)

Date of this Version

10-1-2019

Citation

JOURNAL OF INTERFERON & CYTOKINE RESEARCH Volume 39, Number 10, 2019

DOI: 10.1089/jir.2019.0018

Comments

U.S. government work

Abstract

A meeting entitled, "Interferon Lambda: Disease Impact and Translational Potential," was held on the campus of the National Institutes of Health in Bethesda, Maryland, on October 25-26, 2018. To our knowledge, this was the first meeting that focused exclusively on interferon lambda (IFN-λ). The meeting's purpose was to enhance interdisciplinary communication and promote new collaborations. The gathering brought together an international group of scientists from a wide range of disciplines. Sessions included: IFN-λ Biology, Therapy and Genetic Variation; IFN-λ and Hepatitis C Virus Infection; IFN-λ in Other Infections; and IFN-λ - Hepatic Fibrosis and Cancer. The next meeting on IFN-λ is planned for 2020.